CONTINUING EDUCATION CREDITS
Thrombosis & Hemostasis Summit of North America
August 15-18, 2022 - Chicago, IL
Acknowledgement of Financial Commercial Support
No financial commercial support was received for this educational activity.
Acknowledgement of In-Kind Commercial Support
No in-kind commercial support was received for this educational activity.
Learners must complete an evaluation form to receive a certificate of completion. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and THSNA. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians (ACCME) Credit Designation
Amedco LLC designates this live activity for a maximum of 18.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses (ANCC) Credit Designation
Amedco LLC designates this activity for a maximum of 18.25 ANCC contact hours.
Pharmacists (ACPE) Credit Designation
Amedco LLC designates this activity for a maximum of 18.25 knowledge-based CPE contact hours.
NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.
UAN: UAN JA4008163-9999-22-173-L04-P | UAN JA4008163-9999-22-173-L04-T
This course has been approved by The American Society for Clinical laboratory Science board for 18.00 credit hours.
Objectives - After Attending This Program You Should Be Able To
1. Discuss the basic science of hemostasis and thrombosis, including advances to knowledge in this field that are relevant to bleeding and thrombotic disorders.
2. Discuss important advances in the diagnostic work up of bleeding and thrombotic disorders, including when testing is or is not indicated.
3. Discuss important advances in the treatments available for bleeding and thrombotic disorders, including new anticoagulants and new factor replacement products.
Disclosure of Conflict of Interest
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-‐6.2, 6.5)
All individuals in a position to control the content of CE are listed in the agenda. If their name is not listed below, they disclosed that they had no financial relationships with a commercial interest.
Julia Bayadinova Consultant Fees; Leo Pharma
Meera Chitlur Genentech Inc; Grants/Research, Board Member
Thalia Field Bayer Canada - in-kind study medication; Grant Research
Bob Gosselin Sysmex America, Inc; Diagnostica Grifols; Consultant Fees
Kalpna Gupta Novartis Research Grant for P-selectin Antibody; Grant Research, Novartis; Board Mem/Adv and Honor
Bryce Kerlin HTRS 2020 Mid-Career Research Award (supported by a grant from Genentech, a member of the Roche Group); Novo Nordisk A/S Investigator-Sponsored Study Award; Grants/Research, HEMA Biologics; Board Mem/Adv
Ming Lim HEMA Biologics; Honor
Evelyn Lockhart Lockhart Illustration (owner), Cerus Inc., consultant fee
Nicoletta Machin Takeda Pharmaceutical Company; Grants/Research and Honor/Exp
Stephan Moll Bristol Myers Squibb; Stago Diagnostics; Consultant Fees
Jim Munn Genentech; NovoNordisk; Sanofi-Genzyme; Takeda; Board Mem/Adv
Anand Padmanabhan RETHAM TECHNOLOGIES; Consultant Fees and Stocks and bonds, VERALOX THERAPEUTICS; Boad Mem/ADV, MAYO CLINIC, VERSITI, RETHAM TECHNOLOGIES IP/Royalities
Mark Reding Biomarin; Grants/Research, Bayer, CSL Behring, Hema Biologics, Novo Nordisk, Sanofi Genzyme, Takeda; Board Mem/Adv, Bayer, CSL Behring, Sanofi Genzyme, Takeda; Honor/Exp
Anirban Sen Gupta Haima Therapeutics; Consultant Fees and Board Mem/Adv
Robert Sidonio Takeda (ATHN 9 and SAFE study), Octapharma (MOTIVATE study and Emi PUPs and Nuwiq ITI) and Genentech (Emi PUPs and Nuwiq ITI); Granst/Research, Takeda, Octapharma, Grifols; Consultant Fees, CME events related to VWD; Honor/Exp, ATHN board, MASAC Board Member/Adv
Janice Staber Bayer, Sanofi, Takeda, CSL Behring; Consulting Fees
Oksana Volod Hemonetics; Consulting Fees
Jeffrey Weitz Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi-Sankyo, Ionis, Janssen, Merck, Novartis, Pfizer, Anthos; Consultant Fees
Angela Weyand Takeda, Novo Nordisk, Sanofi; Grants/Research, Takeda; Consultant Fees, Genetech, Sanofi; Board Mem/Adv
Guy Young Genentech, Grifols, Takeda; Grants/Research, Apcintex, Biomarin, Genentech/Roche, Novo Nordisk, Sanofi, Spark, Takeda; Consulting Fees, Apcintex, Biomarin, Genentech/Roche, Novo Nordisk, Sanofi, Spark, Takeda; Honor/Exp
Ayesha Zia Takeda; Board Mem/Adv